Literature DB >> 16127053

Assessment of effective renal plasma flow, enzymuria, and cytokine release in healthy volunteers receiving a single dose of amphotericin B desoxycholate.

Manjunath P Pai1, Jeffrey P Norenberg, Robert A Telepak, David S Sidney, Shu Yang.   

Abstract

The present study assessed potential subclinical markers of amphotericin B (AmB)-related nephrotoxicity and infusion-related reactions (IRR). Subjects were pretreated with diphenhydramine and acetaminophen and received a 500-ml bolus infusion of 0.9% sodium chloride prior to each effective renal plasma flow (ERPF) assessment. ERPF was measured before and after administration of a single 0.25-mg/kg intravenous AmB dose using technetium-99m mercaptoacetyltriglycine. Blood was collected before and 3 h after AmB infusion for tumor necrosis factor alpha (TNF-alpha) and interleukin-1beta (IL-1beta) plasma concentrations. Overnight 12-h urine collections were performed before administration of AmB and for 2 nights after administration of AmB and analyzed for alpha and pi glutathione-S-transferases (GSTalpha and GSTpi, respectively) and N-acetyl-beta-d-glucosaminidase (NAG). Six men and six women with mean +/- standard deviation (SD) ages of 24.8 +/- 5.3 and 28.0 +/- 8.5 years, respectively, were studied. Baseline serum creatinine values were within the normal range and were unaltered after administration of AmB. The mean +/- SD decrease in ERPF after administration of AmB was significant (P < 0.05) in males (15.7 +/- 8.1%) but not females (9.5 +/- 14.0%). The GSTpi and GSTalpha indices increased significantly (P < 0.05) by two to fourfold and returned to baseline in males but were unaltered in females. NAG indices were unaffected by AmB. Six patients experienced an IRR that was associated with increased TNF-alpha (P < 0.05) but not IL-1beta (P = 0.09). These results suggest a potential sex-related difference in AmB-induced nephrotoxicity and provide a rationale for use of ERPF, urine GST, and TNF-alpha as subclinical markers of polyene-induced toxicity.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16127053      PMCID: PMC1195419          DOI: 10.1128/AAC.49.9.3784-3788.2005

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  24 in total

Review 1.  99mTc-MAG3: review of pharmacokinetics, clinical application to renal diseases and quantification of renal function.

Authors:  K Itoh
Journal:  Ann Nucl Med       Date:  2001-06       Impact factor: 2.668

2.  Incidence of and significant risk factors for aminoglycoside-associated nephrotoxicity in patients dosed by using individualized pharmacokinetic monitoring.

Authors:  J S Bertino; L A Booker; P A Franck; P L Jenkins; K R Franck; A N Nafziger
Journal:  J Infect Dis       Date:  1993-01       Impact factor: 5.226

3.  Correlates of acute renal failure in patients receiving parenteral amphotericin B.

Authors:  D W Bates; L Su; D T Yu; G M Chertow; D L Seger; D R Gomes; R Platt
Journal:  Kidney Int       Date:  2001-10       Impact factor: 10.612

4.  Tc-99m mercaptoacetyltriglycine clearance: comparison of camera-assisted methods.

Authors:  M Bocher; Y Shrem; A Tappiser; M Klein; D Schechter; A Taylor; R Chisin
Journal:  Clin Nucl Med       Date:  2001-09       Impact factor: 7.794

5.  Plasma protein binding of amphotericin B and pharmacokinetics of bound versus unbound amphotericin B after administration of intravenous liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate.

Authors:  Ihor Bekersky; Robert M Fielding; Dawna E Dressler; Jean W Lee; Donald N Buell; Thomas J Walsh
Journal:  Antimicrob Agents Chemother       Date:  2002-03       Impact factor: 5.191

6.  The epidemiology of nephrotoxicity associated with conventional amphotericin B therapy.

Authors:  S Harbarth; S L Pestotnik; J F Lloyd; J P Burke; M H Samore
Journal:  Am J Med       Date:  2001-11       Impact factor: 4.965

Review 7.  The role of gender in the progression of renal disease.

Authors:  Sharon R Silbiger; Joel Neugarten
Journal:  Adv Ren Replace Ther       Date:  2003-01

8.  Comparative safety, tolerance, and pharmacokinetics of amphotericin B lipid complex and amphotericin B desoxycholate in healthy male volunteers.

Authors:  V L Kan; J E Bennett; M A Amantea; M C Smolskis; E McManus; D M Grasela; J W Sherman
Journal:  J Infect Dis       Date:  1991-08       Impact factor: 5.226

Review 9.  The role of NAG (N-acetyl-beta-D-glucosaminidase) in the diagnosis of kidney disease including the monitoring of nephrotoxicity.

Authors:  R G Price
Journal:  Clin Nephrol       Date:  1992       Impact factor: 0.975

10.  Glutathione transferases in the urine: sensitive methods for detection of kidney damage induced by nephrotoxic agents in humans.

Authors:  A Sundberg; E L Appelkvist; G Dallner; R Nilsson
Journal:  Environ Health Perspect       Date:  1994-09       Impact factor: 9.031

View more
  4 in total

1.  Section 3: Prevention and Treatment of AKI.

Authors: 
Journal:  Kidney Int Suppl (2011)       Date:  2012-03

Review 2.  Biomarkers of nephrotoxic acute kidney injury.

Authors:  Michael A Ferguson; Vishal S Vaidya; Joseph V Bonventre
Journal:  Toxicology       Date:  2008-01-04       Impact factor: 4.221

3.  Characterization of renal biomarkers for use in clinical trials: biomarker evaluation in healthy volunteers.

Authors:  David A Brott; Scott H Adler; Ramin Arani; Susan C Lovick; Mark Pinches; Stephen T Furlong
Journal:  Drug Des Devel Ther       Date:  2014-02-13       Impact factor: 4.162

4.  Section 4: Contrast-induced AKI.

Authors: 
Journal:  Kidney Int Suppl (2011)       Date:  2012-03
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.